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Background: We report a carbapenem-resistant P. aeruginosa clone responsible for a cluster of urinary tract
infections in elderly surgery patients, diagnosed during a three-month period in a 59-bed surgical clinic.
Findings: The clonal nature of the cluster was established by molecular study of the P. aeruginosa isolates
(PFGE and MLST). Despite an MIC of imipenem in the susceptibility range for two isolates, all were metallo-β
-lactamase-producers (IMP13-type, clone ST621). We conducted a review of the medical and surgical procedures.
We tested water delivered into the clinic and urological devices for the presence of the epidemic strain. The
hygiene nurse observed hygiene practices. A week after the implementation of barrier precautions around the
fourth infected patient, we studied the extent to which the patients hospitalised were colonised to assess whether
the spread of the epidemic strain had been controlled.
Conclusions: 1/ Our findings indicate the difficulties in the detection of the metallo-β-lactamase in this clone,
that resulted in the alert being delayed. 2/ Unlike most investigations of UTI outbreaks described in urology wards,
we did not detect any contaminated urological devices or water colonisation. 3/ Consistent with outbreaks involving
the IMP-13 clone in critical care units, the observation of inadequate application of standard precautions argued for
patient-to-patient transmission during urinary management of the urology patients. 4/ The implementation of barrier
precautions around infected patients resulted in control of the spread of the epidemic clone. This report serves as an
alert concerning a difficult-to-detect multidrug-resistant P. aeruginosa clone in elderly urology patients.Introduction
IMP-type enzymes, the first acquired metallo-β-lactamases
(MBLs) to be detected in Gram-negative pathogens in the
early 1990s, remain among the most prevalent and widely
distributed MBLs. The P. aeruginosa clone ST621, produ-
cing IMP-13 [1], has been responsible for outbreaks in Ital-
ian critical care settings, and has recently been identified in
other European countries and in South America [1-3].
Patient-to-patient transmission of Pseudomonas aeruginosa
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reproduction in any medium, provided the ormulti-drug resistant P. aeruginosa have been described in
neonatal and adult intensive care units, burns units,
oncohaematology units and transplantation units [4].
Outside critical care settings, nosocomial outbreaks of
P. aeruginosa are mostly associated with contaminated
water supplies or inadequately disinfected medical or surgi-
cal devices [5]. In urology wards, P. aeruginosa has been
found to be associated with urinary tract infection (UTI)
outbreaks linked to contaminated urodynamic systems,
cystoscopes or urometers [6], or tap water colonisation [7].
We report a cluster of UTIs associated with a
carbapenem-resistant IMP13-producing P. aeruginosad. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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as an alert concerning a difficult-to-detect and multidrug-
resistant P. aeruginosa clone in elderly urology patients.Methods
The P. aeruginosa isolates from the UTI cases were identi-
fied with Vitek 2 Gram-Negative Identification Cards
(bioMerieux, France). Antibiotic susceptibility was tested by
an agar disk diffusion method. The combined meropenem
+/− dipicolinic acid disk test (Rosco, France) was used for
the phenotypic detection of MBL in isolates displaying de-
creased susceptibility to imipenem according to CLSI and
EUCAST breakpoints (MIC > 4 mg/L). The metallo-β
-lactamase gene, blaIMP-13, was identified in the epidemic
strain as previously described [2]. The isolates were also
characterised by O-serotyping, pulsed-field gel electrophor-
esis (PFGE) and MLST as previously described [8]. We also
studied three unrelated IMP-13-producing P. aeruginosa
recently isolated in distant French regions (named R1 of ST
621, R2 of ST 308 and R3 of ST111).
During the outbreak investigation, we tested water deliv-
ered into the clinic and urological devices for the presence
of the epidemic strain. Environmental samples (n=26) were
taken from water fittings in each medical and surgical unit.
Samples of 200 mL of cold water taken directly from the
tap immediately after activating were filtered and the filters
cultured on plates containing cetrimide medium. Environ-
mental samples were also taken from the four cystoscopes
of the clinic. Plates were incubated at 37°C for 48 hours,
and all bacterial colonies likely to be P. aeruginosa were
identified and studied as described above.
The hygiene nurse observed hygiene practices (materials
and techniques used) in the clinic, to assess if the standard
precautions (for all patients) and the barrier precautions
(around IMP-13-producing P. aeruginosa-infected pa-
tients) were being followed by healthcare workers.
A week after the implementation of barrier precautions
around the fourth infected patient, we studied the extent
to which the patients hospitalised in the clinic were
colonised with the epidemic strain to assess if its spread
had been controlled. Rectal swabs were taken from each
patient for screening. Swabs were immediately suspended
in 0.5 mL of sterile water and 0.1 mL of the suspension
was streaked on a plate containing cetrimide medium.
This study was run in accordance with the French
Healthcare recommendations for the prevention of in-
fection. Ethical approval was obtained at the national
level from the Réseau Alerte Investigation Surveillance
des Infections Nosocomiales (RAISIN). The study was
managed jointly with the director of the clinic, the hy-
giene nurse, surgeons and physicians responsible for car-
ing for the patients, and the regional infection-control
practitioner. Patients and their relatives were enrolledafter an individual interview for consent to allow access
to medical records and to culture a faecal sample.Results
The four clinical cases of UTI
The first case involved a 74-y-old man diagnosed on the
28th of October with a multidrug-resistant imipenem-
intermediate P. aeruginosa UTI, 45 days after prostatec-
tomy, and following imipenem treatment administered for
multidrug-resistant imipenem-susceptible P. aeruginosa
UTI identified one week earlier. The second case was a
90-y-old man diagnosed on the 19th of December with a
multidrug-resistant imipenem-susceptible P. aeruginosa
UTI, 15 days after nephrostomy. Patient 3 (80 y) was diag-
nosed on the 6th of January with a multidrug-resistant
imipenem-susceptible P. aeruginosa UTI, one day after
cystography and during a period when he was undergoing
numerous urological surgical interventions. The fourth
patient was a woman (89 y) diagnosed on the 16th of
January with a multidrug-resistant imipenem-intermediate
P. aeruginosa UTI, one month after nephrostomy. In all
cases, UTIs were defined on the basis of clinical signs of
infection and biological criteria (significant leukocyturia
and bacteriuria).Detection of the IMP-13-producing P. aeruginosa
The MICs of imipenem were 8 mg/L for isolates from pa-
tients 1 and 4. The P. aeruginosa isolates associated with
these UTIs exhibited a high level of resistance to
ceftazidime (>256 mg/L). Following the French Healthcare
recommendations, the two isolates showing a decreased
susceptibility to imipenem (MIC=8 mg/L) were screened
for MBL. Both isolates were found to be MBL-producers.
The clonal nature of the two isolates was established from
the PFGE patterns of the isolates. As a consequence of
these findings, a retrospective study of P. aeruginosa UTIs
was conducted. Two UTIs associated with ceftazidime-
resistant P. aeruginosa isolates were identified in patients
2 and 3; the MICs of imipenem were 4 mg/L for both iso-
lates. We studied the two ceftazidime-resistant imipenem-
susceptible P. aeruginosa isolates recovered from patients
2 and 3, even though their susceptibility to imipenem was
not below the threshold value. These isolates were also
MBL-producers. The clonal nature of the UTI cluster
was then established from the PFGE patterns of the four
isolates (Figure 1). All belonged to serogroup O:4, and
were identified as being IMP13-type and members of
clone ST621, also called the Italian clone. These inves-
tigations therefore established a cluster of four UTIs as-
sociated with an IMP-13-producing epidemic strain,
diagnosed during a three-month period in a 59-bed sur-
gical clinic in Chartres, France.
Figure 1 Pulsed-field gel electrophoresis patterns of the four UTI-associated IMP-13 P. aeruginosa isolates (C1-C4), the ten colonising
isolates recovered from carriers (R1-R10), the four environmental isolates recovered from water samples (W1-W4), and three
epidemiologically unrelated IMP-13 P. aeruginosa reference isolates (ref. 1–3). 1PFGE pattern recovered in the course of colonisation study
for the previously infected patient C4.
Milan et al. Antimicrobial Resistance and Infection Control 2013, 2:12 Page 3 of 5
http://www.aricjournal.com/content/2/1/12Review of procedures and techniques, and analysis of
environmental samples and hygiene practices
A review of the medical and surgical procedures, and other
techniques performed by the medical staff, did not reveal
any factor common to the infected patients. P. aeruginosa
isolates were recovered from four water samples collected
from water fittings in the urological surgical unit, but none
of these isolates exhibited high levels of resistance to any of
the antibiotics tested. In addition, PFGE and MLST dem-
onstrated that these environmental isolates were genetic-
ally distant from the epidemic IMP-13 strain (Figure 1).
None of the environmental samples from the cystoscopes
was positive for P. aeruginosa. Observations by the hygiene
nurse revealed that the barrier precautions around IMP-
13-producing P. aeruginosa-infected patient 4 were being
followed by healthcare workers. By contrast, the applica-
tion of standard precautions was not optimal, as hand hy-
giene practices were inadequate, especially for urinary
management and/or the manipulation of urinary catheters,
and before cystography. Overall, these observations suggest
that transmission between patients was not likely to have
been associated with surgery, invasive acts or contaminated
water supplies, but with urinary managment.Nosocomial acquisition of the IMP-13 P. aeruginosa after
implementation of barrier precautions
On the 23th of January, all patients hospitalised in the
clinic, were screened for the epidemic strain. Nine of the
55 patients (16%), all urology patients, were positive for P.
aeruginosa carriage. PFGE and MLST showed genetically
diverse colonising isolates and that none presented the
IMP13-type (Figure 1). Note that the colonising isolate
(R1) of ST 621 and presenting the PFGE IMP13 pattern,
was recovered from patient 4, who was still hospitalised at
the time of the colonisation study. In addition, no epi-
demic strain was recovered from any patient at the clinic
during the following six months, suggesting that the
spread of the epidemic isolate in the clinic had been
controlled.
Discussion
Our results document the spread of the IMP13-producing
clone in a small private surgical clinic, rather than in an
intensive care unit of a university hospital as previously
described for this clone.
For two of the four isolates, the MIC of carbapenem
drugs was in the susceptibility range. Consequently, the
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weeks. Our findings confirm the previously described
heterogeneous carbapenem-resistance phenotype of the
IMP13-producing clone [9] and suggest that the spread
of the clone may be, at least partially, facilitated by diffi-
culties in its detection.
Despite extensive investigations prompted by this clus-
ter of UTIs associated with the IMP-13 P. aeruginosa,
no evidence was found for the involvement of the water
supplies or contaminated medical or surgical devices. It
is possible that the delay between the time of contamin-
ation of the patients and our investigations hindered the
identification of a contaminated source. However, in all
but one case, the time separating surgery and invasive
acts from the onset of clinical signs of UTI was long.
These observations do not argue for contamination of
the patients during surgery or invasive acts.
By contrast, the temporal superposition of hospitalisa-
tion for the infected patients, and the observation of in-
sufficiently strict application of hygiene practices in the
urology unit and before cystography suggest that the UTI
cases may have resulted from cross-transmission during
post-surgery hospitalisation. The rate of faecal carriage of
P. aeruginosa among elderly urology patients is fre-
quently high, confirming the ability of this bacterium to
colonise the urinary tract of such patients [10]. In view
of the frequent and invasive nature of urinary care acts
following surgery, and the well-described epidemic po-
tential of the IMP-13 clone [1,3,11], we suggest that eld-
erly urology patients should be considered to be at high
risk of patient-to-patient cross-transmission of IMP-13-
producing P. aeruginosa.
Concordant with MLST results, the recent sequence
analysis of the blaIMP13 gene in numerous IMP-13-P.
aeruginosa isolates from distant French regions showed
that our epidemic isolates and the Italian clone have very
similar characteristics [12]. Nevertheless, no link with
countries experiencing IMP-13-P. aeruginosa outbreaks
was identified in the index case history, and the origin of
the IMP-13 clone involved in this outbreak remains un-
clear. Further studies are needed to improve our know-
ledge of the epidemiology of this highly resistant clone.
Because of the association between the use of broad-
spectrum antibiotics and multidrug resistance, a campaign
has been run to promote systematic microbiological docu-
mentation of UTI: this should favour the use of specific
rather than broad-spectrum antibiotics. The early imple-
mentation of barrier precautions around infected pa-
tients successfully prevented the further spread of the
carbapenem-resistant clone in the clinic. We suggest
that, when facing a limited cluster of infections, such pre-
cautions may be sufficient for infection control, without
the need for more extreme measures, such as cohorting,
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